• Version
• Download 69
• File Size 0.00 KB
• File Count 1
• Create Date July 9, 2020
• Last Updated September 30, 2022

China Mandatory Period Risk Evaluation Report and the latest PMS Requirements in NMPA and FDA

Did you know China, the second-largest medical device and in vitro diagnostic (IVD) industry market globally, is the only market with a 20 percent annual growth rate year after year?

Are you up to speed on the hundreds of new regulations introduced by China’s National Medical Products Administration (NMPA) — formally known as the China Food and Drug Administration?

What are the strategic factors to consider during the reform before your submission?

Attached Files